Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.

Original languageEnglish
Pages (from-to)381-387
Number of pages7
JournalCurrent Opinion in Hematology
Volume18
Issue number6
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Hematopoietic Stem Cell Transplantation
Residual Neoplasm
Acute Myeloid Leukemia
Hematopoietic Stem Cells
Recurrence
Flow Cytometry
Leukemia
Color
Transplants
Polymerase Chain Reaction
Technology
Antigens
Sensitivity and Specificity
Genes

Keywords

  • allogeneic hematopoietic stem cell transplant
  • leukemia relapse
  • minimal residual disease

ASJC Scopus subject areas

  • Hematology

Cite this

@article{4c54515129b34e3c9ecbb41a5baadf7d,
title = "Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia",
abstract = "Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.",
keywords = "allogeneic hematopoietic stem cell transplant, leukemia relapse, minimal residual disease",
author = "Alida Dominietto",
year = "2011",
month = "11",
doi = "10.1097/MOH.0b013e32834bac7d",
language = "English",
volume = "18",
pages = "381--387",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

AU - Dominietto, Alida

PY - 2011/11

Y1 - 2011/11

N2 - Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.

AB - Purpose of review: This study will review the role of minimal residual disease (MRD) in predicting leukemia relapse following an allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML). Recent findings: PCR and multiparameter flow cytometry (MFC) assays are the most important methods of identifying MRD. PCR technique allows to recognize early genetic abnormalities of residual leukemic cells with high specificity and sensitivity. MFC assay using six-color to 10-color technology is an alternative option for MRD monitoring in AML patients without gene markers to detect leukemia-associated immunophenotype antigens (LAIPs). Summary: Despite the evidence that early detection of MRD after allogeneic HSCT is associated with a high risk of hematological relapse, it is still unclear whether this information can be translated into clinical practice, in order to prevent hematological relapse.

KW - allogeneic hematopoietic stem cell transplant

KW - leukemia relapse

KW - minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=80054717409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054717409&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e32834bac7d

DO - 10.1097/MOH.0b013e32834bac7d

M3 - Article

C2 - 21986564

AN - SCOPUS:80054717409

VL - 18

SP - 381

EP - 387

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 6

ER -